Vast Therapeutics

Vast Therapeutics

Vast Therapeutics

Novoclem develops inhalable treatments for antibioticresistant pathogens present in cystic fibrosis and other respiratory disease patients. Anne Whitaker is set to complete preclinical stage of development.
Raised
$15M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$15,000,000
Venture capital (Series A) - 2019
Cystic Fibrosis Foundation Shionogi
Team Size
1–10
Employees
FinSMEs

Vast Therapeutics Closes Series A Funding